ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

New York, June 08, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Intravenous IV Solutions Market 2023-2027" - https://www ...

The intravenous fluid shortage continues to hinder hospitals nationwide. The American Society of Health-System Pharmacists and the University of Utah Drug Information Service have compiled a fact ...

Oct. 31 (UPI) --A North Carolina facility is leading efforts to restore the nation's depleted supply of IV solutions after Hurricane Helene temporarily put it out of business. The shortage of IV ...

Oct 31 (Reuters) - Medical device maker Baxter International (BAX.N), opens new tab said on Thursday it has restarted the highest-throughput intravenous solutions manufacturing line at its North ...

Amid Hurricane Helene shuttering a major IV solution manufacturing plant and Hurricane Milton now barreling toward other IV manufacturing facilities in central Florida, the American Hospital ...

A recent shortage of intravenous (IV) solutions, most acutely affecting normal saline solutions, has prompted concerns across the nation. This most recent incident adds to a growing list of products ...

Intravenous (IV) solutions are a complete mix of essential nutrients which are intended to replenish fluid losses, treat electrolyte imbalances and maintain fluid balance in intravenous therapy. They ...

When pharmacist Rita K. Jew saw a robot that mixes intravenous drugs at an industry event, she instantly knew she wanted it for her own hospital. “This is definitely a breakthrough in technology,” ...

Baxter’s North Cove site made about 60% of the U.S. supply of IV fluids. Demand has recovered since the hurricane, but not as much as Baxter had expected. Grade told investors in an October earnings ...

ISSUE: FDA and the Centers for Disease Control and Prevention (CDC) are continuing to investigate multiple instances of Wallcur's simulated intravenous (IV) saline products being administered to ...